CHÂTILLON, France and WARREN, N.J., June 2026
DBV Technologies announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the VIASKIN® Peanut Patch in infants aged 6 to 12 months with peanut allergy. The study marks an important milestone in the company’s strategy to expand its epicutaneous immunotherapy platform into younger patient populations and explore the potential benefits of early intervention in food allergy management.
Advancing Early Intervention for Peanut Allergy
The THRIVE study is designed to evaluate the efficacy and safety of the VIASKIN® Peanut Patch in helping infants with peanut allergy achieve ad lib consumption of dietary peanut, allowing consumption based on individual tolerance and clinical assessment. Researchers believe that infancy may represent a critical window during which immune responses can be influenced, potentially improving long-term allergy outcomes through early therapeutic intervention.
According to study investigators, recent research has highlighted the importance of introducing therapeutic strategies during early childhood when immune system adaptability is at its highest. The initiation of participant screening in THRIVE is expected to generate valuable clinical insights into the role of epicutaneous immunotherapy (EPIT) in very young children diagnosed with peanut allergy.
THRIVE Study Design and Objectives
Advertisement
The Phase 2 THRIVE trial is a single-arm, open-label study in which enrolled participants will wear the VIASKIN® Peanut Patch daily for 36 months while maintaining a peanut-free diet. Following this treatment period, participants will undergo a controlled peanut food challenge to evaluate their ability to tolerate peanut exposure and determine the next phase of the study.
Based on individual responses, some participants may discontinue patch therapy and enter a monitored peanut consumption period, while others may continue treatment. The study aims to assess whether long-term exposure through the skin can help train the immune system and potentially modify the course of peanut allergy. The trial will also evaluate safety outcomes and long-term treatment tolerability in this young patient population.
Expanding the VIASKIN® Peanut Development Program
DBV Technologies is building on encouraging clinical experience from previous studies involving toddlers and young children. The company believes that extending evaluation into infants could provide a unique opportunity to investigate whether earlier intervention can produce greater immunological benefits and improve long-term outcomes.
Company leadership noted that the THRIVE study supports its broader mission to transform the management of food allergies through non-invasive immunotherapy approaches. By leveraging the skin’s natural immune properties, the VIASKIN® platform is designed to deliver microgram quantities of allergens without injections or oral administration, potentially offering a convenient treatment option for patients and caregivers.
As recruitment progresses, data generated from THRIVE may help define future development strategies for peanut allergy treatment and contribute to a growing body of research focused on disease modification through early immune intervention.
Source: DBV Technologies press release
